Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to ...

By Nancy Lapid (Reuters) -People who take weight-loss drugs hoping to achieve the impressive results observed in large ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

GLP-1 investors haven’t gained as much as expected from others’ losses. Since the FDA approved Wegovy, also known as ...

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

Madison Investments, an investment advisor, released its “Madison Sustainable Equity Strategy” first quarter 2025 investor ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

Hims & Hers Health Inc. shares slid over 2.8% on Tuesday and continued declining after-hours trading after Eli Lilly ...

News outlets break down the health effects rubber bullets and tear gas have on people, and how the use of such methods could open up governments to civil liability claims. Other states making news: ...

McDonald's faces a potential decline in sales due to the weight loss medications. Other fast-food chains like Domino's and KFC are also at risk, while Taco Bell and Chipotle are better positioned.

Weight loss drugs like Ozempic and Wegovy are used by over 15 million adults in the U.S., or 4.5% of the population. Despite ...

Obesity-drug makers have signed deals that could be worth $812 million to a South San Francisco company and more than $650 million to a Redwood City company. How a $200K UC Berkeley grant could launch ...